Ceria Nanoparticles Fabricated with 6‐Aminohexanoic Acid that Overcome Systemic Inflammatory Response Syndrome

Systemic inflammatory response syndrome (SIRS) is self‐destructive and uncontrollable inflammatory response of the whole body triggered by infection, trauma, or a variety of severe injuries. Although reactive oxygen species play a pivotal role in the development of SIRS, the trials with conventional...

Full description

Saved in:
Bibliographic Details
Published in:Advanced healthcare materials 2019-05, Vol.8 (9), p.e1801548-n/a
Main Authors: Jeong, Han‐Gil, Cha, Bong Geun, Kang, Dong‐Wan, Kim, Do Yeon, Yang, Wookjin, Ki, Seul‐Ki, Kim, Song I, Han, Juhee, Kim, Chi Kyung, Kim, Jaeyun, Lee, Seung‐Hoon
Format: Article
Language:English
Subjects:
6‐aminohexanoid acid
Animal models
Antioxidants
cerium oxide nanoparticles
Cerium oxides
Clinical trials
Inflammation
Inflammatory response
Injury prevention
Nanoparticles
Nanotechnology
nanotherapeutics
Reactive oxygen species
Scavenging
Systemic inflammatory response syndrome
Trauma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic inflammatory response syndrome (SIRS) is self‐destructive and uncontrollable inflammatory response of the whole body triggered by infection, trauma, or a variety of severe injuries. Although reactive oxygen species play a pivotal role in the development of SIRS, the trials with conventional antioxidants have failed to improve patient outcome. Ceria nanoparticles (CeNPs) have potent, autocatalytic reactive oxygen species scavenging activities, which may have sufficient therapeutic effects for SIRS. Herein, 3 nm CeNPs are fabricated totally in aqueous phase by using 6‐aminohexanoic acid (6‐AHA) and their Ce3+ to Ce4+ ratio is increased to enhance antioxidative properties. The obtained 6‐AHA‐CeNPs demonstrate strong antioxidative and anti‐inflammatory effects in various biofluids and inflammatory cells. In SIRS animal models, 6‐AHA‐CeNPs are demonstrated to reduce multiple organ injuries and inflammation. Moreover, 6‐AHA‐CeNPs decrease mortality and improve clinical scores of SIRS models. These findings suggest that 6‐AHA‐CeNPs have potential as a therapeutic nanomedicine for SIRS. Systemic inflammatory response syndrome (SIRS) is a complex, self‐destructive process that occurs when the local control is lost and inflammation is overactivated throughout the body. Ceria nanoparticles (CeNPs) synthesized in aqueous phase using 6‐aminohexanoic acid (6‐AHA‐CeNPs) effectively treat remote organ injuries and improve survival rate in SIRS animal models.
ISSN:2192-2640
2192-2659
DOI:10.1002/adhm.201801548